The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira)

On 4 August 2015, the EU Commission approved the acquisition by Pfizer of Hospira, a US-based competitor in, amongst other areas, biosimilar drugs and sterile injectable drugs. In order to obtain approval, Pfizer agreed to a number of divestments designed to eliminate actual or potential overlaps in the parties’ product

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Porter Elliott, The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira), 4 August 2015, e-Competitions Merger Remedies, Art. N° 75437

Visites 385

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues